These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31348619)

  • 21. Multicenter clinical experience with the Afirma gene expression classifier.
    Alexander EK; Schorr M; Klopper J; Kim C; Sipos J; Nabhan F; Parker C; Steward DL; Mandel SJ; Haugen BR
    J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
    San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
    Geng Y; Aguilar-Jakthong JS; Moatamed NA
    Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
    Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
    Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
    [No Abstract]   [Full Text] [Related]  

  • 25. Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up.
    Angell TE; Frates MC; Medici M; Liu X; Kwong N; Cibas ES; Kim MI; Marqusee E
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1477-83. PubMed ID: 26353010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
    Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
    Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ThyroSeq
    Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
    Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
    Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
    Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries.
    Agarwal S; Bychkov A; Jung CK; Hirokawa M; Lai CR; Hong S; Kwon HJ; Rangdaeng S; Liu Z; Su P; Kakudo K; Jain D
    Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis.
    Vuong HG; Nguyen TPX; Hassell LA; Jung CK
    Cancer Cytopathol; 2021 Mar; 129(3):182-189. PubMed ID: 32726885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF; Westra WH; Cooper DS; Ali SZ
    Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
    Selvaggi SM
    Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How "suspicious" is that nodule? Review of "suspicious" Afirma gene expression classifier in high risk thyroid nodules.
    Roychoudhury S; Klein M; Souza F; Gimenez C; Laser A; Shaheen Cocker R; Chau K; Das K
    Diagn Cytopathol; 2017 Apr; 45(4):308-311. PubMed ID: 28188700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules.
    Harrison G; Sosa JA; Jiang X
    Arch Pathol Lab Med; 2017 Jul; 141(7):985-989. PubMed ID: 28467214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
    Zhu QL; Faquin WC; Samir AE
    AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
    Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
    Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules.
    Polavarapu P; Fingeret A; Yuil-Valdes A; Olson D; Patel A; Shivaswamy V; Matthias TD; Goldner W
    J Endocr Soc; 2021 Nov; 5(11):bvab148. PubMed ID: 34708178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usage trends and performance characteristics of a "gene expression classifier" in the management of thyroid nodules: An institutional experience.
    Samulski TD; LiVolsi VA; Wong LQ; Baloch Z
    Diagn Cytopathol; 2016 Nov; 44(11):867-873. PubMed ID: 27534929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.